HA545 Unit 8 Sickle Cell Gene Therapy Equity Paper Example

A Cure Priced in Millions for a Disease Long Underfunded: A Health Equity Policy Paper on Medicaid Access to Sickle Cell Gene Therapy Under the Federal Cell and Gene Therapy Access Model in a Composite State, Asking Who Bears the Burden, What the Policy Changed and Whom It Still Misses

[Student Name]

Purdue University Global

HA545: Health Policy

Unit 8 Health Equity Policy Paper

[Instructor Name]

[Date]

The state, its program figures and the hospital are composite and bracketed for the writer's own data; the federal approvals, model and research cited are real.

Equity, Defined

Equality is offering the same policy to everyone; equity is designing policy so that outcomes become more equal. For sickle cell disease, an equal approach, covering gene therapy on the same terms as any other costly treatment, could still leave the people most affected without it, because the barriers lie in where they live, how they are covered and which centers can deliver the treatment.

Who Bears the Burden

Sickle cell disease affects roughly [100,000] Americans, most of them Black, and average life expectancy remains about [20] years shorter than for the general population (Kavanagh et al., 2022). Repeated pain crises, strokes and organ damage shape lives from childhood. Research funding has lagged: per person affected, sickle cell disease has received far less federal and foundation research funding than cystic fibrosis, a genetic disease of similar severity that mostly affects White Americans (Farooq et al., 2020). Patients also describe long waits for pain treatment in emergency departments and being treated as drug seekers. In the composite state, about [3,100] people live with the disease; an estimated [58] percent are covered by Medicaid. The first cures arrived for a disease whose patients have long waited longer for everything, from research dollars to pain medicine.

What the Policy Changed

In December 2023, the Food and Drug Administration approved the first two gene therapies for sickle cell disease, for people [12] and older with severe disease (U.S. Food and Drug Administration, 2023). At their prices, a state Medicaid program could face tens of millions of dollars for a few dozen patients. In 2024, the CMS Innovation Center launched the Cell and Gene Therapy Access Model: CMS negotiates with manufacturers on behalf of participating states, setting prices and outcomes-based terms, such as rebates if the therapy does not work as expected, and states agree to cover the therapy on common terms. The composite state joined the model in [year]. It covers gene therapy for eligible Medicaid members at [two] authorized treatment centers, with coverage for travel and lodging during the months of treatment, and a care coordinator for each patient.

Why Outcomes-Based Payment Matters Here

A one-time therapy priced in millions creates a timing problem for a state budget: the full cost arrives in one year, while the benefits, fewer hospital stays and emergency visits, arrive over decades and may accrue partly to other payers if a patient later changes coverage. Outcomes-based terms shift some of the risk back to the manufacturer. If a treated patient's disease returns or hospital use does not fall as expected, the state receives a rebate. For a Medicaid program, this makes the decision to cover less of a bet on uncertain evidence and more a purchase of results. It also gives the state a reason to track outcomes it had rarely measured for this population.

Early Evidence

The model is new, and few patients have completed treatment. In its first [year], the state approved [11] patients for evaluation, and [four] completed therapy. Clinical trial results suggest most treated patients stop having severe pain crises, but long-term durability and late effects are not yet known. The state's figures come from its own reports and should be read as early.

Whom It Still Misses

Patients far from treatment centers. Therapy requires months near a center for cell collection, chemotherapy conditioning and recovery. Travel coverage helps, but caregivers must leave work and children must leave school. Patients who cannot tolerate conditioning. The chemotherapy needed to prepare the bone marrow carries serious risks, including infertility, and some patients with organ damage are not eligible. Fertility preservation. Many patients want to preserve fertility before conditioning, but Medicaid coverage for egg or sperm freezing is limited; in the composite state it is not covered. People covered by private plans. The model covers Medicaid only; commercial plans make their own coverage decisions. Adults with years of distrust. Some patients, after years of poor treatment, hesitate to enroll in an intensive therapy, and few clinicians outside major centers can counsel them. Capacity. The two centers can treat about [eight] patients a year each, limited by transplant beds and staff.

Measuring Equity in the Program

Counting treated patients is not enough. The state should track, by region, age and payer history, how many eligible patients were referred, how many were evaluated, how many began treatment and why others stopped. A gap between referral and treatment in one region would point to distance; a gap among adults would point to distrust or eligibility. The state should also track outcomes for patients who do not pursue gene therapy, so that attention to the newest treatment does not pull resources from the majority who rely on everyday care.

The Hospital's Role

The composite academic hospital is one of two authorized centers. It has had to build a referral pathway from community hematologists, add a gene therapy coordinator, reserve transplant beds, negotiate with the state on lodging, and track outcomes required by the model. Its emergency department, which sees many sickle cell patients, also adopted an individualized pain plan for each known patient, an equity step unrelated to gene therapy but raised by the same patients.

Recommendations by Actor

State Medicaid agency: cover fertility preservation for gene therapy candidates and fund caregiver lodging. Hospitals and centers: add outreach clinics in underserved regions and train community clinicians to counsel patients. State legislature: fund a statewide sickle cell program to coordinate care for patients who do not pursue gene therapy. Federal government: consider extending outcomes-based arrangements to Medicare and encouraging commercial plans to participate.

Limits

The model's terms between CMS and manufacturers are not fully public. Because the price and rebate terms are confidential, an outside reviewer cannot judge whether the state pays less than it would have alone, which limits any assessment of cost-effectiveness for now. Outcome data are early, and the composite figures are illustrative.

Conclusion

The federal model removed the biggest barrier, price, for Medicaid patients. Access still depends on distance, fertility, trust and center capacity, and those barriers fall on the same people who have long waited longest.

References

Farooq, F., Mogayzel, P. J., Lanzkron, S., Haywood, C., & Strouse, J. J. (2020). Comparison of US federal and foundation funding of research for sickle cell disease and cystic fibrosis and factors associated with research productivity. JAMA Network Open, 3(3), e201737. https://doi.org/10.1001/jamanetworkopen.2020.1737

Kavanagh, P. L., Fasipe, T. A., & Wun, T. (2022). Sickle cell disease: A review. JAMA, 328(1), 57-68. https://doi.org/10.1001/jama.2022.10233

U.S. Food and Drug Administration. (2023). FDA approves first gene therapies to treat patients with sickle cell disease. https://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapies-treat-patients-sickle-cell-disease